Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gilead Sciences IRAK4 compound 22
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
01
Overview
Gilead Sciences IRAK4 compound 22: sourced facts only. name: "This thiadiazole series, exemplified by compounds 19 and 22, has shown promise for potent, selective, orally bioavailable IRAK4 inhibitors." [PMID:41531974]; target: "This thiadiazole series, exemplified by compounds 19 and 22, has shown promise for potent, selective, orally bioavailable IRAK4 inhibitors." [PMID:41531974]; developer: "Gilead Sciences Inc., 333 Lakeside Drive, Foster City, California 94404, United States." [PMID:41531974]
02
Targets
IRAK4 (Interleukin-1 receptor associated kinase 4)
Beyond the preview
Go deeper on Gilead Sciences IRAK4 compound 22.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gilead Sciences IRAK4 compound 22.